Due to the limitations of the consent provided by the patients in our study, and restrictions imposed by our funders we cannot make the data generally available. The UPBEAT Scientific Advisory Committee accept applications for use of data from those who make a formal request, providing a description of the intended study on a research application form (UPBEAT RAF) available from Glen Nishku (<glen.nishku@gstt.nhs.uk>). Providing the proposed studies do not conflict with consent, the data will be freely available.

Introduction {#sec005}
============

For most healthcare professionals and pregnant women, gestational diabetes mellitus (GDM) diagnosis is understood to be a binary categorisation of hyperglycaemia versus normoglycaemia. This is despite a well-established linear increase in risk of adverse outcomes across the glycaemic spectrum \[[@pone.0230658.ref001]\], and the potential for pathophysiological heterogeneity of GDM with diverse maternal and offspring outcomes \[[@pone.0230658.ref002]\].

Hyperglycaemia in pregnancy is widely accepted to result from an imbalance between rising insulin resistance and inadequate insulin secretion, yet specific mechanisms likely differ between, and amongst phenotypic groups. Amongst obese women for example, excessive insulin resistance is considered to be the predominant pathophysiological mechanism, whereas insulin secretory defects may predominate in lean women with GDM \[[@pone.0230658.ref002]--[@pone.0230658.ref005]\]. This distinction was corroborated in a recent study in which biochemical and clinical heterogeneity were described in women with GDM, classified as GDM with an insulin secretion defect, GDM with an insulin sensitivity defect, and mixed defects. The authors reported that women with a predominant insulin sensitivity defect were those with a higher BMI \[[@pone.0230658.ref002]\].

Health care professionals appreciate that women with GDM will require different treatment modalities according to their ability to control glycaemia. While this may reflect disease severity, maternal lifestyle or adherence to treatment, diverse underlying disease processes may also be contributory. Improved understanding of the pathophysiology could facilitate management through delineation of subtypes of GDM, enabling targeted therapy \[[@pone.0230658.ref006]\].

We have previously shown that obese women with GDM have differing metabolic profiles from obese women without GDM and that this is evident prior to diagnosis \[[@pone.0230658.ref007]\]. Using the same dataset, we have hypothesised that the measured analytes might further distinguish between groups necessitating diverse treatment approaches to achieve glucose control. Metabolite phenotypes were therefore compared between women allocated to different GDM treatment strategies in a proof of principle exploratory study. To our knowledge, there has been no previous attempt to define subgroups according to measured analytes, and by treatment strategy.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

This prospective cohort study was a secondary analysis utilising data from the UK Pregnancies Better Eating and Activity Trial (UPBEAT, ISRCTN 89971375), a multicentre RCT of a complex dietary and physical activity intervention designed to prevent GDM in obese women and reduce the incidence of LGA infants \[[@pone.0230658.ref008]\]. Women with a pre-existing diagnosis of essential hypertension, diabetes, coeliac disease, thyroid disease, renal disease, systemic lupus erythematosus, antiphospholipid syndrome, sickle-cell disease, thalassaemia, current psychosis, or a current prescription of metformin were excluded. The UPBEAT trial (recruitment 2009 to 2014), included 1555 women; they were \>16 years of age, had a Body Mass Index (BMI) ≥30kg/m^2^ and a singleton pregnancy. Women were randomised between 15^+0^ and 18^+6^ weeks' gestation to either a behavioural intervention superimposed on standard antenatal care or standard antenatal care. All aspects of the trial, including the analyses for the present study were approved by the NHS Research Ethics Committee (UK Integrated Research Application System; reference 09/H0802/5) and all participants, including women aged 16 and 17 using Fraser guidelines, provided informed written consent \[[@pone.0230658.ref008]\].

Participants {#sec008}
------------

A complete-case analysis was undertaken and included all women from the control arm of UPBEAT who had undertaken a diagnostic Oral Glucose Tolerance Test (OGTT), with documented GDM treatment modality and complete biochemical data at trial entry, at the time of GDM testing and in late pregnancy (*n* = 300). Women were excluded if these criteria were not met, if GDM was diagnosed by local thresholds but did not fulfil diagnostic criteria according to the trial protocol (*n* = 3), or who fulfilled the trial protocol diagnostic criteria, but not local criteria for GDM diagnosis (*n* = 23).

Procedures {#sec009}
----------

Sociodemographic and clinical data, and non-fasting blood samples were collected at time point 1 (15--18^+6^ gestational weeks'; mean 17^+0^). The trial protocol specified that an OGTT should be performed between 27 and 28^+6^ gestational weeks', however a clinically pragmatic approach has been adopted for the purposes of this study with inclusion of OGTTs undertaken between 23^+3^ and 29^+6^ (mean 27^+5^). A research blood sample was collected at the time of the OGTT fasting sample (time point 2). Diagnosis of GDM was according to International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria (fasting glucose ≥5.1 mmol/l, 1 hr ≥10.0 mmol/l, 2 hr ≥8.5 mmol/l) in response to an oral 75g glucose load \[[@pone.0230658.ref009]\]. A non-fasting blood sample was collected at time point 3 (34--36^+0^ gestational weeks', mean 34^*+6*^). Pregnancy outcome data was recorded shortly after delivery.

The main outcome of interest was GDM treatment modality following diagnosis. Women were subcategorised into: No-GDM; GDM Diet Group (treated with diet only); GDM Metformin Group (treated with metformin); GDM Insulin Group (treated with insulin alone or metformin plus insulin). Study centres reported that GDM treatment most frequently began with dietary advice, followed by the addition of metformin and then insulin if control was not achieved, either due to glycaemic severity or poor compliance. Modality was recorded as the treatment at the time of delivery.

Metabolic profiling {#sec010}
-------------------

Analytes were measured in plasma and serum samples using a combination of NMR spectroscopy and conventional assays. A high-throughput targeted NMR metabolomic platform was utilised (<http://www.computationalmedicine.fi/platform>). The quantitative NMR measures include numerous lipid species, fatty acids, amino acids, and markers of glucose homeostasis and has been used widely in population-based studies of insulin resistance and metabolic disease \[[@pone.0230658.ref010]--[@pone.0230658.ref014]\]. The methodology has been described previously \[[@pone.0230658.ref015]\]. Analytes measured using conventional laboratory platforms ([S1 Table](#pone.0230658.s001){ref-type="supplementary-material"}) included glucose homeostasis markers, sex hormone binding globulin (SHBG), gamma glutamyl transferase (gGT) and adiponectin. For the purposes of this study and to restrict multiple comparisons, only those analytes identified previously as different between women with GDM and women without GDM at the time of diagnosis (time point 2) \[[@pone.0230658.ref007]\] were explored. A total of 89 analytes, 83 from the NMR metabolome, were evaluated.

Statistical analysis {#sec011}
--------------------

The distribution of data for each analyte was checked for normality and those with non-parametric distribution log-transformed. Relationships between the concentration of variables and gestational age were explored; none required transformation.

Analyte data at time points 1, 2 and 3 were compared by treatment modality group by multivariate regression analyses, with No-GDM as the baseline group for comparison. Standard Deviation (SD) differences between each treatment category and No-GDM are reported to enable comparison between analytes with differing units of measurement. Exploratory analyses compared women treated by insulin with those treated by diet.

An *a priori* decision based on known associations identified age and BMI as confounders for the multivariate analyses. Each regression was clustered by centre.

Pregnancy outcomes between GDM treatment groups were compared using either one-way ANOVA or the Kruskal Wallis test depending on the distribution of data.

Due to small numbers and the exploratory nature of this investigation, no sensitivity analyses were undertaken, although differences between women with GDM included and those excluded, were investigated. No formal correction for multiple testing was undertaken and statistical significance was assumed at a *p* value \<0.05.

Statistical analysis was performed using Stata software, version 14.0 (StataCorp LP, College Station, Texas).

Results {#sec012}
=======

Of the 664 women in the control arm of UPBEAT, 300 with complete biochemical data were included (median BMI 35 kg/m^2^, Interquartile range (IQR) 32.8--38.2). Of these, 229 did not develop GDM (No-GDM group); 71 (24%) developed GDM, of whom 28 (39%) were treated by diet (Diet Group); 20 (28%) with metformin (Metformin Group); and 23 (32%) with insulin (Insulin Group; 9 insulin alone, 13 insulin plus metformin) ([S1 Fig](#pone.0230658.s006){ref-type="supplementary-material"}).

Participant characteristics and pregnancy outcome by treatment modality are summarised in [Table 1](#pone.0230658.t001){ref-type="table"}. Comparison between women with GDM included in this study compared to those excluded are shown in [S2 Table](#pone.0230658.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0230658.t001

###### Maternal clinical factors and pregnancy outcome by treatment modality in women with and without GDM.

![](pone.0230658.t001){#pone.0230658.t001g}

                                                            No GDM              GDM                                     
  --------------------------------------------------------- ------------------- ------------------- ------------------- -------------------
  **Maternal factors (collected time point 1)**                                                                         
  **Age (years)**                                           30.5 (5.5)          32.7 (4.8)          31.6 (5.9)          32.2 (5.1)
  **Blood pressure (mmHg)**                                                                                             
  Systolic                                                  118.7 (10.8)        123.5 (12.5)        119.2 (7.3)         118.8 (8.3)
  Diastolic                                                 72.7 (7.7)          75.3 (7.8)          72.1 (5.8)          72.8 (6.0)
  **BMI (kg/m**^**2**^**)**                                 34.8 (32.7--37.8)   35 (32.4--39.5)     36.1 (33.5--39.9)   37.4 (34.6--40)
  **Ethnicity**                                                                                                         
  African                                                   20 (8.7)            9 (32.1)            3 (15)              2 (8.7)
  African Caribbean                                         12 (5.2)            4 (14.3)            1 (5)               1 (4.3)
  South Asian                                               17 (7.4)            1 (3.6)             2 (10)              1 (4.3)
  European                                                  161 (70.3)          12 (42.9)           12 (60)             16 (69.6)
  Other                                                     19 (8.3)            2 (7.1)             2 (10)              3 (13)
  **Parity**                                                                                                            
  Nulliparous                                               111 (48.5)          10 (35.7)           11 (55)             13 (56.5)
  **Current Smoking**                                       14 (6.1)            1 (3.6)             1 (5)               2 (8.7)
  **Centre**                                                                                                            
  St Thomas\' Hospital                                      62 (27.1)           19 (67.9)           12 (60)             8 (34.8)
  Newcastle                                                 43 (18.8)           4 (14.3)            4 (20)              0 (0)
  Glasgow                                                   67 (29.3)           2 (7.1)             3 (15)              11 (47.8)
  Manchester                                                24 (10.5)           1 (3.6)             0 (0)               2 (8.7)
  Bradford                                                  12 (5.2)            0 (0)               0 (0)               1 (4.3)
  St Georges Hospital                                       21 (9.2)            2 (7.1)             1 (5)               1 (4.3)
  **OGTT results**                                                                                                      
  Fasting glucose                                           4.5 (0.3)           4.9 (0.5)           5.4 (0.6)           5.4 (0.6)
  1hr glucose                                               7.4 (1.4)           9.7 (1.8)           11.4 (1.5)          10.7 (1.8)
  2hr glucose                                               5.5 (1.1)           6.8 (1.2)           7.5 (1.2)           7.4 (1.8)
  **Gestational age (weeks)**                                                                                           
  Time point 1                                              16.9 (1.1)          17.2 (1.1)          17.1 (1.0)          17.5 (0.9)
  Time point 2                                              27.7 (0.7)          27.8 (0.6)          27.9 (0.6)          27.8 (0.5)
  Time point 3                                              34.9 (0.8)          34.7 (0.5)          34.7 (0.5)          34.5 (0.5)
  **Pregnancy outcomes**                                                                                                
  Preeclampsia                                              8 (3.5)             2 (7.1)             1 (5)               2 (9.1)
  PPH                                                       34 (14.8)           5 (17.9)            2 (10)              6 (26.1)
  Weight change (Kg)[\*](#t001fn001){ref-type="table-fn"}   2.7 (2.1)           1.0 (2.4)           -1.0 (2.0)          1.0 (2.6)
  NICU                                                      7 (3.1)             4 (14.3)            0 (0)               3 (13)
  Apgar \<7 at 1 min                                        3 (1.3)             1 (3.6)             0 (0)               1 (4.3)
  Preterm birth                                             4 (1.7)             1 (3.6)             1 (5)               0 (0)
  CS all                                                    77 (33.6)           11 (39.3)           6 (30)              11 (47.8)
  CS emergency                                              45 (19.7)           7 (25)              4 (20)              5 (21.7)
  GA at delivery                                            40.6 (39.3--41.4)   39.8 (38.8--40.6)   38.6 (38.1--39.2)   38.3 (37.9--38.6)
  Birthweight (g)                                           3545.4 (487.9)      3386.4 (556.1)      3288.5 (360.1)      3314.6 (379.4)
  SGA (customised centile)                                  23 (10)             5 (17.9)            1 (5)               1 (4.3)
  BW (customised centile)                                   44.1 (22.8--68.1)   51.5 (20.9--76.2)   53.2 (30.3--76.3)   64.1 (40.7--81.5)
  LGA (customised)                                          15 (6.6)            3 (10.7)            1 (5)               3 (13)

\*weight change between time point 2 and 3, GDM gestational diabetes, SD standard deviation, IQR interquartile range, OGTT oral glucose tolerance test, PPH post-partum haemorrhage, NICU neonatal intensive care, CS caesarean section, GA gestational age, SGA small for gestational age, BW birthweight, LGA large for gestational age. Time point 1---mean 17^+0^ weeks, time point 2---mean 27^+5^ weeks, time point 3---mean 34^+6^ weeks, missing data: systolic and diastolic blood pressure---5, Apgar---2, 1hr glucose---16

The analyte profiles are illustrated by a representative subset (*n* = 22) of different metabolite groups (Figs [1](#pone.0230658.g001){ref-type="fig"}--[3](#pone.0230658.g003){ref-type="fig"}). Metabolite absolute values at each time point for this subset are shown in [S3](#pone.0230658.s003){ref-type="supplementary-material"}--[S5](#pone.0230658.s005){ref-type="supplementary-material"} Tables. Absolute values and graphical representation for all measured analytes are available on request.

![Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 1, 10 weeks before diagnosis/treatment (mean 17^+0^ weeks').\
Data points show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown to the right, negative to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA saturated fatty acid to total fatty acid ratio.](pone.0230658.g001){#pone.0230658.g001}

![Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 2, at time of OGTT (mean 27^+5^ weeks').\
Data points show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown to the right, negative to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA saturated fatty acid to total fatty acid ratio.](pone.0230658.g002){#pone.0230658.g002}

![Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 3, following treatment (mean 34^+6^ weeks').\
Data points show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown to the right, negative to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA saturated fatty acid to total fatty acid ratio.](pone.0230658.g003){#pone.0230658.g003}

Analytes by treatment modality {#sec013}
------------------------------

### Diet, metformin and insulin groups {#sec014}

*Time point 1; 10 weeks before diagnosis/treatment (random blood sample)*. At least 10 weeks before OGTT and initiation of treatment, differences between the metabolic profiles of treatment modality groups were identified ([Fig 1](#pone.0230658.g001){ref-type="fig"}, [S3 Table](#pone.0230658.s003){ref-type="supplementary-material"}). Greater concentrations of total lipids within VLDL were observed in the pharmacologically treated groups (Metformin and Insulin Groups), whereas women in the Diet Group demonstrated VLDL lipid concentrations similar to those who did not develop GDM. The Diet group had larger large density lipoprotein (LDL) and HDL particles compared to No-GDM women, whereas the pharmacologically treated groups had larger VLDL particles. Women in the Metformin Group had lower polyunsaturated fatty acid: total fatty acid ratios (PUFA:TFA) and higher saturated fatty acid:total fatty acid ratios (SFA:TFA) than No-GDM women. The branched-chain amino acid isoleucine was higher in women in the Metformin Group than in women without GDM. Non-fasting glucose was higher than No-GDM in Diet, Metformin and Insulin Groups. Amongst the women eventually treated with insulin, the non-fasting insulin concentration varied widely and was no different from No-GDM women. This contrasted with a significantly higher insulin pre-treatment concentration in the Diet and Metformin Groups than in women without GDM ([Fig 1](#pone.0230658.g001){ref-type="fig"})

*Time point 2; at OGTT (fasting blood sample)*. At time point 2, the time of GDM diagnosis but prior to treatment initiation, divergence in analytes between the groups had widened ([Fig 2](#pone.0230658.g002){ref-type="fig"}, [S4 Table](#pone.0230658.s004){ref-type="supplementary-material"}). The Insulin Group had higher concentrations of total lipids in most VLDL subclasses than women without GDM. A similar trend was seen in the Metformin Group. Women in the Diet Group, in contrast, had lower total lipids in small VLDL, higher total lipids in very large and large HDL subclasses and lower VLDL cholesterols compared to women without GDM. VLDL particle size, total triglycerides and triglycerides in both VLDL and HDL were greater in the Insulin Group than women without GDM. In the Diet Group HDL and LDL particle size were greater. The PUFA:TFA ratio was lower in both the metformin and insulin treated groups than No-GDM women. Monounsaturated fatty acid:total fatty acid ratios (MUFA:TFA) and SFA:TFA were greater in the Metformin and Insulin Groups respectively. Isoleucine was higher in the women ultimately treated by metformin. In this fasting sample, glucose and insulin were significantly higher only in the Metformin and Insulin Groups ([Fig 2](#pone.0230658.g002){ref-type="fig"}, [S4 Table](#pone.0230658.s004){ref-type="supplementary-material"}).

*Time point 3; following treatment (random blood sample)*. The mean duration of treatment, from diagnosis to blood draw at time point 3, was 7.1 weeks' (range 4.9--12, SD 0.9). As only final treatment modality was recorded, the number of weeks on this treatment was unknown. Differences in lipid species and other analytes observed at the time of the OGTT between Diet and No-GDM groups remained evident after treatment, with an additional greater difference in total VLDL lipids between these groups at the later time point. Similar trends were also maintained between the Insulin and No-GDM Groups, although treatment was associated with convergence towards the No-GDM profile. 'Normalisation' towards the No-GDM group was evident following treatment with metformin (Metformin Group), including glucose and insulin, with differences remaining only for total triglycerides and triglycerides in HDL, and alanine ([Fig 3](#pone.0230658.g003){ref-type="fig"}).

*Gestational profile of glucose and total triglycerides in Insulin versus Diet Groups*. Figs [4](#pone.0230658.g004){ref-type="fig"} and [5](#pone.0230658.g005){ref-type="fig"} illustrate the gestational profile of total triglyceride and glucose concentrations of No-GDM, Diet and Insulin Groups. At time points 2 and 3 triglycerides were greater in the Insulin Group compared to the Diet-treated women, with no difference between the Diet Group and women without GDM. At time point 2 (fasting sample), glucose concentration in the Insulin Group was higher than both women treated with diet and those without GDM, with no difference between these latter groups.

![Total triglyceride measurements in diet treated, insulin treated and No-GDM women at 3 gestational time points across pregnancy.\
time point 2 (mean 27^+5^ weeks') was fasting. 95% CI, not adjusted. \* *p* value \<0.05.](pone.0230658.g004){#pone.0230658.g004}

![Glucose measurements in diet treated, insulin treated, and No-GDM women at 3 gestational time points across pregnancy.\
time point 2 (mean 27^+5^ weeks') was fasting. 95% CI, not adjusted. \* *p* value \<0.05.](pone.0230658.g005){#pone.0230658.g005}

Discussion {#sec015}
==========

To our knowledge there has been no previous attempt to assess the metabolic profile in GDM in obese women according to the three conventional modalities of treatment; diet, metformin and insulin. Whilst, as might be anticipated, treatment led towards convergence of analytes towards the 'norm', we also identified differing analyte profiles early in pregnancy amongst women, according to their eventual treatment regime.

Comparison between treatment groups {#sec016}
-----------------------------------

The rationale for treatment of GDM with diet or a pharmacological approach is generally based on severity of hyperglycaemia, but we suggest that these clinical practices may be unintentionally predicated, at least in part, by aetiological differences. Trends in analyte concentrations were most evident from early gestation between women in whom GDM was treated with diet and those treated with insulin; throughout pregnancy, women ultimately treated with insulin exhibited a more insulin resistant profile, whereas women whose glycaemia was ultimately controlled by diet demonstrated a markedly non-insulin resistant profile which could indicate a different pathway to GDM, possibly through insufficient secretion of insulin.

The gestational profile of insulin resistance identified from early pregnancy onwards in the Insulin and to a lesser degree, the Metformin Groups, as defined by the NMR spectrum, also included higher lipid constituents of VLDL subclasses, lower HDL constituents and smaller LDL particle size, a profile described previously in non-pregnant insulin resistant subjects \[[@pone.0230658.ref016]--[@pone.0230658.ref018]\]. Of potential relevance, an 'Insulin Resistance Score' based on similar indices measured by NMR is now commercially available for type 2 diabetes mellitus (T2DM) risk assessment in non-pregnant individuals \[[@pone.0230658.ref019]\] and a similar scoring system could be envisaged for determining GDM risk.

Similarly, the fatty acid and amino acid profiles characteristic of insulin resistance, as observed in the women with GDM, have been identified previously in non-pregnant populations, particularly higher monounsaturated and saturated fatty acids, and branched-chain amino acids \[[@pone.0230658.ref013], [@pone.0230658.ref020]\].

Women treated for GDM *v* women without GDM {#sec017}
-------------------------------------------

When comparing the treatment groups to women without GDM, differences in metabolite profiles were also evident from the earliest point of measurement, many weeks before treatment; the Metformin and Insulin Groups already demonstrating an 'unfavourable', more insulin resistant profile, incorporating amongst other markers, higher total lipids in VLDL subclasses and larger VLDL particle size. Women ultimately treated with diet did not share these characteristics; total lipids in VLDLs were similar in concentration to No-GDM women, and LDL and HDL particles were larger. As expected, all three groups exhibited higher glucose concentrations than women without GDM. At the time of GDM diagnosis, the divergence in analytes between groups was particularly striking; the Diet Group now showed a more favourable lipid profile than the women without GDM, in contrast to raised insulin resistance markers in the insulin-treated group. The Metformin Group showed intermediate lipid values, although with an unfavourable fatty acid and amino acid profile. In accordance with aetiological diversity amongst groups, women treated only with metformin, and women requiring insulin were unable to maintain normoglycaemia on fasting (time point 2), whereas glucose and insulin concentrations in the Diet Group were similar to women without GDM.

Different GDM subgroups of obese women? {#sec018}
---------------------------------------

The inference that the obese women treated with diet may represent a distinct subgroup is supported by a previous study inferring diverse pathways leading to GDM amongst BMI heterogeneous women. Similar differences in fasting glucose and insulin concentrations to those we describe between diet and insulin treated groups were identified in women with GDM defined by a poor insulin secretion profile (fasting glucose 76mg/dl; 72--79, fasting insulin 6.0μl/ml; 4.6--6.7) or those with an insulin resistant profile (90mg/dl; 81--94, 13.6μl/ml 9.9--20.5) respectively \[[@pone.0230658.ref002]\].

The consistently 'lower' insulin resistant profile in the diet treated group throughout pregnancy and following treatment, adds strength to the case for a different aetiology between groups, and we hypothesise that women in this study cohort whose GDM is treatable by diet may represent a sub group with a poor insulin secretion profile. This is supported by the observation that following treatment, glucose homeostasis remained abnormal, with relative hyperglycaemia and hyperinsulinaemia (non-fasting). In contrast, insulin resistance markers in women treated with metformin, converged towards those in women without GDM after treatment, with additional improvements in glucose and insulin concentration. Women in the Insulin Group did not achieve a similar degree of 'normalisation', but interpretation is limited as the glycaemic control achieved is unknown.

A difference in gestational age at delivery was evident between GDM treatment groups, likely reflecting the clinical approach to the timing of delivery between these groups. However, despite differing underlying pathophysiological processes and potential severity of disease, other pregnancy outcomes between treatment groups did not differ significantly ([Table 1](#pone.0230658.t001){ref-type="table"}), although this may reflect the small numbers in each group.

Strength and weaknesses {#sec019}
-----------------------

We believe there has been no previous exploration of mechanistic heterogeneity of treatment groups using metabolic profiling amongst obese women.

This is a proof of concept study involving a subgroup analysis of a large cohort; although women included were demographically similar to those not included, it is a potential weakness that data may be missing not at random (MNAR) \[[@pone.0230658.ref021]\].

Based on a known effect of the UPBEAT intervention on metabolite profiles \[[@pone.0230658.ref022]\], a decision was made *a priori* to explore subgroups in the control arm of the trial only. It is accepted that this resulted in a reduction in the number of women in the GDM treatment groups, which is a limitation of this study.

This, the first detailed description of metabolic profiles in relation to treatment in women with GDM prompts further and more detailed investigation; confirmation of phenotypic subgroups as indicated by metabolic analyses is required amongst a larger patient sample, and different ethnic subgroups. Measurement of more specific markers of insulin secretion and sensitivity could further define pathophysiological subgroups.

The UPBEAT trial did not have a standardised protocol for GDM treatment which may have differed between centres, although analyses were clustered by centre to minimise bias. As GDM treatment modality was obtained following delivery, the time of initiation and cessation of treatment was commonly not recorded. No formal correction for multiple testing was undertaken because of the exploratory nature of the analysis and the small sample size.

In summary, targeted metabolomic analyses have suggested diverse profiles according to treatment modality. Confirmation in larger populations is required and if validated could provide a rationale for early stratification and appropriate therapy.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As detailed by the second reviewer please why the metabolites were measured in the control group and not in the intervention arm as well? in addition, the small sample size needs to be recognised as a limitation

We would appreciate receiving your revised manuscript by Jan 04 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.
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We look forward to receiving your revised manuscript.

Kind regards,

Stephen L Atkin, MD

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

3\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4\. One of the noted authors is a group or consortium: UPBEAT Consortium

In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

5\. Thank you for stating the following in the Competing Interests section:

SMN discloses receipt of lecture/other fees from Roche Diagnostics, outside the scope of this work. DAL discloses receipt of fees from Roche Diagnostics and Ferring Pharmaceuticals for research unrelated to this paper. All other authors declare that there is no declaration of interest associated with their contribution to this manuscript.

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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12 Dec 2019

Referee 2 made two comments which required a response and amendment of the manuscript.

"I was left wondering, and perhaps many other readers will be, why the metabolites were measured in the control group and not in the intervention arm as well? I think the paper would have been more interesting if they reported on both groups. The number of subjects in the GDM groups was very small, and this should be acknowledged as one of the limitations."

We have responded with the following addition to the discussion text:

"Based on a known effect of the UPBEAT intervention on metabolite profiles (Mills HL et al.), a decision was made a priori to explore subgroups in the control arm of the trial only. It is accepted that this resulted in a reduction in the number of women in the GDM treatment groups, which is a limitation of this study."

10.1371/journal.pone.0230658.r003
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Dear Dr White,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

please address the statistical queries that have been raised

==============================

We would appreciate receiving your revised manuscript by Apr 12 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Stephen L Atkin, MD

Academic Editor

PLOS ONE
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author
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Reviewer \#3: Table 1- some of the data is n and %, but this heading is not included. Add with mean (sd) and median (IQR).

Discussion/ stats methods: the discussion states: "Despite differing underlying pathophysiological processes and potential severity of disease, outcomes between treatment groups did not differ significantly (Table 1)" List in the manuscript the statistical methods used to determine this.

Consider showing 95% confidence intervals for the outcomes listed in table 1 to further show the lack of differences in outcome between treatment groups.
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Reviewer 3 made three comments which required a response or amendment of the manuscript.

1\. "Table 1 -- some of the data is n and %, but this heading is not included. Add with mean (sd) and median (IQR)."

We are grateful for this observation and we have updated the table as requested.

2\. "Discussion/stats methods: the discussion states: 'Despite differing underlying pathophysiological processes and potential severity of disease, outcomes between treatment groups did not differ significantly (Table 1) -- list in the manuscript the statistical methods used to determine this".

We have added the following sentence at the end of 'Statistical Analysis' in the Materials and Methods section (P8, L150-151):

"Pregnancy outcomes between GDM treatment groups were compared using either one-way ANOVA or the Kruskal Wallis test depending on the distribution of data."

3\. "Consider showing 95% confidence intervals for the outcomes listed in table 1 to further show the lack of differences in outcome between treatment groups."

Thank you for this suggestion. As noted, one-way ANOVA and Kruskal Wallis were used to compare outcomes between treatment groups. These methods do not calculate 95% CI.

4\. We should like to add a comment (P17, L314-315) regarding differences in gestational age at delivery between the groups, previously omitted. We noted this difference when double checking the data for this revision -- our apologies for this oversight. The difference resonates with current clinical practice and may be of interest to the reader.

10.1371/journal.pone.0230658.r005
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Dear Dr. White,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Stephen L Atkin, MD

Academic Editor

PLOS ONE
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Dear Dr. White:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Stephen L Atkin

Academic Editor

PLOS ONE
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